(2E)-1-(3-Chlorophenyl)-3-(4-chlorophenyl)prop-2-en-1-one | 1211528-57-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (2E)-1-(3-Chlorophenyl)-3-(4-chlorophenyl)prop-2-en-1-one
• 英文别名: (E)-1-(3-chlorophenyl)-3-(4-chlorophenyl)prop-2-en-1-one
• CAS: 1211528-57-2
• 化学式: C₁₅H₁₀Cl₂O
• 分子量: 277.15
• InChiKey: ZAEJRVCUOPUWCC-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2E)-1-(3-Chlorophenyl)-3-(4-chlorophenyl)prop-2-en-1-one 、 2-氨基-5-巯基-1,3,4-噻二唑 以 乙醇 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  An Interactive Human Carbonic Anhydrase-II (hCA-II) Receptor - Pharmacophore Molecular Model & Anti-Convulsant Activity of the Designed and Synthesized 5-Amino-1,3,4-Thiadiazole-2-Thiol Conjugated Imine Derivatives

  摘要：

  New imines, derived from aromatic aldehyde, chalcones and 5‐amino‐1,3,4‐thiadiazole‐2‐thiol exhibited promising anti‐convulsant activity which is explained through chemo‐biological interactions at receptor site producing the inhibition of human Carbonic Anhydrase‐II enzyme (hCA‐II) through the proposed pharmacophore model at molecular levels as basis for pharmacological activity. The compounds 5‐{1‐(4‐Chlorophenyl)‐3‐[4‐(methoxy‐phenyl)‐prop‐2‐en‐1‐ylidene]amino}‐1,3,4‐thiadiazole‐2‐thiol (2b), 5‐{[1‐(4‐chloro‐phenyl)]‐3‐[4‐(dimethyl‐amino‐phenyl)‐prop‐2‐en‐1‐ylidene]amino}‐1,3,4‐thiadiazole‐2‐thiol (2c) and 5‐{[1‐(4‐chloro‐phenyl)]‐3‐[(4‐amino‐phenyl)‐prop‐2‐en‐1‐ylidene]amino}‐1,3,4‐thiadiazole‐2‐thiol (2f) showed 100% activity in comparison with standard Acetazolamide, a known anti‐convulsant drug. The compounds 2c, 2f also passed the Rotarod and Ethanol Potentiation tests which further confirmed them to be safe in motor coordination activity and safe from generating neurological toxicity.

  DOI：

  10.1111/cbdd.12113
• 作为产物：
  描述：

  4-氯苯甲醛 、 3-氯苯乙酮 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 (2E)-1-(3-Chlorophenyl)-3-(4-chlorophenyl)prop-2-en-1-one
  参考文献：
  名称：

  An Interactive Human Carbonic Anhydrase-II (hCA-II) Receptor - Pharmacophore Molecular Model & Anti-Convulsant Activity of the Designed and Synthesized 5-Amino-1,3,4-Thiadiazole-2-Thiol Conjugated Imine Derivatives

  摘要：

  New imines, derived from aromatic aldehyde, chalcones and 5‐amino‐1,3,4‐thiadiazole‐2‐thiol exhibited promising anti‐convulsant activity which is explained through chemo‐biological interactions at receptor site producing the inhibition of human Carbonic Anhydrase‐II enzyme (hCA‐II) through the proposed pharmacophore model at molecular levels as basis for pharmacological activity. The compounds 5‐{1‐(4‐Chlorophenyl)‐3‐[4‐(methoxy‐phenyl)‐prop‐2‐en‐1‐ylidene]amino}‐1,3,4‐thiadiazole‐2‐thiol (2b), 5‐{[1‐(4‐chloro‐phenyl)]‐3‐[4‐(dimethyl‐amino‐phenyl)‐prop‐2‐en‐1‐ylidene]amino}‐1,3,4‐thiadiazole‐2‐thiol (2c) and 5‐{[1‐(4‐chloro‐phenyl)]‐3‐[(4‐amino‐phenyl)‐prop‐2‐en‐1‐ylidene]amino}‐1,3,4‐thiadiazole‐2‐thiol (2f) showed 100% activity in comparison with standard Acetazolamide, a known anti‐convulsant drug. The compounds 2c, 2f also passed the Rotarod and Ethanol Potentiation tests which further confirmed them to be safe in motor coordination activity and safe from generating neurological toxicity.

  DOI：

  10.1111/cbdd.12113

文献信息

• [EN] THIENO- AND FURO[2,3-D]PYRIMIDINE-2,4[1H,3H]-DIONE DERIVATIVES AS TRPC5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS DE THIÉNO- ET FURO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE À TITRE DE MODULATEURS DES TRPC5 POUR LE TRAITEMENT DES TROUBLES NEUROPSYCHIATRIQUES
  申请人：HYDRA BIOSCIENCES INC

  公开号：WO2016023832A1

  公开（公告）日：2016-02-18

  This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula (I), and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. A, R1, R2, R3 and R4 have meanings given in the description.

  这项发明涉及公式（I）的新型噻吩和呋喃[2,3-d]嘧啶-2,4[1H,3H]-二酮衍生物，以及它们作为TRPC5调节剂的用途，含有这些衍生物的药物组合物，以及将其用作TRPC5受体介导的疾病或症状的治疗剂的方法。其中，A、R1、R2、R3和R4的含义见说明。
• THIENO- AND FURO[2,3-d]PYRIMIDINE-2,4[1H,3H]-DIONE DERIVATIVES
  申请人：Hydra Biosciences, Inc.

  公开号：US20160039841A1

  公开（公告）日：2016-02-11

  This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula I and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. A, R 1 , R 2 , R 3 and R 4 have meanings given in the description.

  本发明涉及公式I的新型噻吩和呋喃[2,3-d]嘧啶-2,4[1H,3H]-二酮衍生物及其作为TRPC5调节剂的用途，包含其药物组成物，以及将其作为TRPC5受体介导的疾病或症状的治疗剂的方法。其中，A，R1，R2，R3和R4的含义在说明中给出。
• THIENO- AND FURO[2,3-D]PYRIMIDINE-2,4[1H,3H]-DIONE DERIVATIVES AS TRPC5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
  申请人：Hydra Biosciences, Inc.

  公开号：EP3180345B1

  公开（公告）日：2018-10-10
• US9447114B2
  申请人：——

  公开号：US9447114B2

  公开（公告）日：2016-09-20